{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:15:48Z","timestamp":1788628548980,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Stroke and Cerebrovascular Diseases"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jstrokecerebrovasdis.2018.08.030","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T00:56:32Z","timestamp":1536886592000},"page":"3605-3612","source":"Crossref","is-referenced-by-count":35,"title":["Trends of Antiplatelet Therapy for the Management of Moyamoya Disease in Japan: Results of a Nationwide Survey"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-3337","authenticated-orcid":false,"given":"Koichi","family":"Oki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0617-125X","authenticated-orcid":false,"given":"Masahiro","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikane","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohiro","family":"Houkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0001","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S1474-4422(08)70240-0","article-title":"Moyamoya disease: current concepts and future perspectives","volume":"7","author":"Kuroda","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0002","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2176\/nmc.52.245","article-title":"Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis)","volume":"52","year":"2012","journal-title":"Neurol Med Chir"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0003","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1161\/STROKEAHA.113.004386","article-title":"Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial","volume":"45","author":"Miyamoto","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0004","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.10.003","article-title":"Effects of surgery and antiplatelet therapy in ten-year follow-up from the registry study of research committee on moyamoya disease in Japan","volume":"25","author":"Yamada","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0005","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3171\/foc.1998.5.5.8","article-title":"Long-term outcome after STA-MCA anastomosis for moyamoya disease","volume":"5","author":"Miyamoto","year":"1998","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0006","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/01.STR.28.6.1170","article-title":"Effects of surgical revascularization on outcome of patients with pediatric moyamoya disease","volume":"28","author":"Ishikawa","year":"1997","journal-title":"Stroke"},{"issue":"Suppl 2","key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0007","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/S0303-8467(97)00075-9","article-title":"Direct and indirect revascularization for moyamoya disease surgical techniques and peri-operative complications","volume":"99","author":"Houkin","year":"1997","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0008","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-1331.2011.03481.x","article-title":"What is the expert's option on antiplatelet therapy in moyamoya disease? Results of a worldwide Survey","volume":"19","author":"Kraemer","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0009","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1046\/j.1440-1789.2000.00300.x","article-title":"Moyamoya disease","volume":"20","author":"Fukui","year":"2000","journal-title":"Neuropathology"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0010","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.wneu.2017.06.057","article-title":"Effect of aspirin in postoperative management of adult ischemic moyamoya disease","volume":"105","author":"Zhao","year":"2017","journal-title":"World Neurosurg"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0011","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.wneu.2010.01.005","article-title":"Trends in the management of adult moyamoya disease in the United States: results of a nationwide survey","volume":"73","author":"Andaluz","year":"2010","journal-title":"World Neurosurg"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009942","article-title":"Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study)","volume":"6","author":"Onozuka","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0013","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2176\/nmc.52.295","article-title":"Epidemiological features of moyamoya disease in Japan","volume":"52","author":"Hoshino","year":"2012","journal-title":"Neurol Med Chir"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0014","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/STROKEAHA.106.478297","article-title":"Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease: results of multicenter survey in Japan","volume":"38","author":"Kuroda","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0015","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00415-009-5425-7","article-title":"Primary central nervous system vasculitis and moyamoya disease: similarities and differences","volume":"257","author":"Kraemer","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0016","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1161\/STROKEAHA.107.513408","article-title":"Moyamoya disease in Europeans","volume":"39","author":"Kraemer","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0017","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/jnnp.2007.130666","article-title":"Novel epidemiological features of moyamoya disease","volume":"79","author":"Baba","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0018","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0303-8467(97)00037-1","article-title":"A survey of moyamoya disease in Hawaii","volume":"99","author":"Graham","year":"1997","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0019","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2176\/nmc.ra.2014-0305","article-title":"Asymptomatic moyamoya disease: literature review and ongoing AMORE study","volume":"55","author":"Kuroda","year":"2015","journal-title":"Neurol Med Chir"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0020","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2018.08.030_bib0021","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1161\/01.STR.0000209620.44017.97","article-title":"The risks and safety of clopidogrel in pediatric arterial ischemic stroke","volume":"37","author":"Soman","year":"2006","journal-title":"Stroke"}],"container-title":["Journal of Stroke and Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305718304841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305718304841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T01:44:36Z","timestamp":1571881476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052305718304841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1052305718304841"],"URL":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2018.08.030","relation":{},"ISSN":["1052-3057"],"issn-type":[{"value":"1052-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}